title: Effects of poststroke losartan versus captopril treatment on myogenic and endothelial function in the cerebrovasculature of SHRsp.
abstract: OBJECTIVE
  We assessed the ability of poststroke captopril and losartan treatment to reverse myogenic and endothelial dysfunction in the middle cerebral arteries of Kyoto-Wistar stroke-prone spontaneously hypertensive rats (SHRsp) that developed intracerebral hemorrhagic stroke.
  
  
  METHODS
  SHRsp were sampled before and after stroke development and after up to 37 days of captopril (50 mg/kg per day) or losartan (35 mg/kg per day) treatment initiated after stroke. Pressure-dependent constriction to a 100-mm Hg pressure step, constriction to nitric oxide synthase inhibition (100 micromol/L N(omega)-nitro-l-arginine methyl ester), and endothelium-dependent vasodilation to bradykinin (1.6 micromol/L), 2-f-LIGRLO-NH(2) (1 micromol/L, a protease-activated receptor-2 agonist), and A23187 (2 micromol/L) were evaluated in middle cerebral arteries at 100 mm Hg with a pressure myograph.
  
  
  RESULTS
  Middle cerebral arteries from SHRsp with stroke could not constrict to pressure or nitric oxide synthase inhibition, lacked the ability to vasodilate to bradykinin, and exhibited attenuated dilation and vasomotion in response to A23187. Vasodilation to 2-f-LIGRLO-NH(2) was unaltered. The aforementioned cerebrovascular alterations were reversed after 31 days of poststroke losartan but not of captopril treatment in the absence of an antihypertensive effect. Captopril treatment restored middle cerebral artery constriction to pressure, NOS inhibition, and bradykinin vasodilation temporarily after 7 to 18 days of treatment, after which function deteriorated to a level observed in SHRsp at stroke.
  
  
  CONCLUSIONS
  Aspects of poststroke cerebrovascular dysfunction, which likely play an important role in altering and modulating cerebral blood flow autoregulation, can be reversed in SHRsp more effectively after stroke development by blocking angiotensin II type 1 receptors as opposed to lowering angiotensin II levels.
authors: Division of Basic Medical Sciences, Memorial University, Health Science Center, St John's, Newfoundland, Canada. jsmeda@mun.ca
authors: John S
authors: JS
authors: Smeda
authors: John J
authors: JJ
authors: McGuire
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D002216:Captopril / Q000494:pharmacology*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004730:Endothelium, Vascular / Q000187:drug effects; D019808:Losartan / Q000494:pharmacology*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D044140:Receptor, Angiotensin, Type 1 / Q000187:drug effects; D020521:Stroke / Q000150:complications / Q000188:drug therapy*; D014652:Vascular Diseases / Q000188:drug therapy / Q000209:etiology; D014664:Vasodilation / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D044140:Receptor, Angiotensin, Type 1; D002216:Captopril; D019808:Losartan